Fabenol® Max and ‘reduces the absorption of carbohydrates’

Tabs

Article
Fabenol® Max, kidney bean extract, carbohydrate absorption, health claims
First published in the EFSA Journal
23 February 2016
Adopted
2 February 2016
Type
Scientific Opinion
Abstract

Following an application from Ecopharma BVBA, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Fabenol® Max and ‘reduces the absorption of carbohydrates’. The Panel considers that Fabenol® Max, which is an aqueous extract from Phaseolus vulgaris L. standardised by its content of α-amylase inhibitor, is sufficiently characterised. According to the applicant, consumption of the food ‘offers potential benefits in the maintenance of healthy blood sugar levels’. The meaning of ‘healthy blood sugar levels’ was not specified. The target population proposed by the applicant is ‘the general population that wants to manage their carbohydrate intake (for the maintenance of healthy blood sugar levels or optimal body composition)’. The Panel notes that the claimed effect was not sufficiently defined and that the applicant did not provide any further information. The Panel concludes that a cause and effect relationship cannot be established between the consumption of Fabenol® Max and a beneficial physiological effect.

Panel members at the time of adoption
Jean Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry McArdle, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Daniel Tomé, Dominique Turck, Hendrik Van Loveren, Marco Vinceti and Peter Willatts
Panel on Dietetic Products, Nutrition and Allergies
Contact
nda [at] efsa.europa.eu
doi
10.2903/j.efsa.2016.4401
EFSA Journal 2016;14(2):4401 [8 pp.].
Question Number
On request from
Competent Authority of Belgium following an application by Ecopharma BVBA
Print on demand
Number of Pages
8